ATE453657T1 - Verfahren zur herstellung von 3alpha(beta)- - Google Patents
Verfahren zur herstellung von 3alpha(beta)-Info
- Publication number
- ATE453657T1 ATE453657T1 AT06763188T AT06763188T ATE453657T1 AT E453657 T1 ATE453657 T1 AT E453657T1 AT 06763188 T AT06763188 T AT 06763188T AT 06763188 T AT06763188 T AT 06763188T AT E453657 T1 ATE453657 T1 AT E453657T1
- Authority
- AT
- Austria
- Prior art keywords
- 3alpha
- beta
- producing
- alkyl
- cholanic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
- C07J9/005—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane containing a carboxylic function directly attached or attached by a chain containing only carbon atoms to the cyclopenta[a]hydrophenanthrene skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Seasonings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000912A ITMI20050912A1 (it) | 2005-05-19 | 2005-05-19 | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
PCT/EP2006/062446 WO2006122977A2 (en) | 2005-05-19 | 2006-05-19 | PROCESS FOR PREPARING 3α(β)-7α(β)-DIHYDROXY-6α(β)-ALKYL-5β-CHOLANIC ACID |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE453657T1 true ATE453657T1 (de) | 2010-01-15 |
Family
ID=35841713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT06763188T ATE453657T1 (de) | 2005-05-19 | 2006-05-19 | Verfahren zur herstellung von 3alpha(beta)- |
Country Status (12)
Country | Link |
---|---|
US (1) | US7994352B2 (de) |
EP (1) | EP1888614B1 (de) |
JP (1) | JP5127700B2 (de) |
CN (1) | CN101203526B (de) |
AT (1) | ATE453657T1 (de) |
AU (1) | AU2006248906B2 (de) |
CA (1) | CA2608539C (de) |
DE (1) | DE602006011457D1 (de) |
DK (1) | DK1888614T3 (de) |
ES (1) | ES2338698T3 (de) |
IT (1) | ITMI20050912A1 (de) |
WO (1) | WO2006122977A2 (de) |
Families Citing this family (98)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE303399T1 (de) | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
US10987362B2 (en) | 2004-03-12 | 2021-04-27 | Intercept Pharmaceuticals, Inc. | Treatment of fibrosis using FXR ligands |
PL1734970T3 (pl) | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
ES2438271T3 (es) | 2007-01-19 | 2014-01-16 | Intercept Pharmaceuticals, Inc. | Ácidos biliares 23-sustituidos como moduladores de TGR5 y métodos de uso de los mismos |
CN105037476B (zh) | 2008-07-30 | 2018-06-12 | 英特塞普特医药品公司 | Tgr5调节剂及其使用方法 |
DK2698375T3 (en) | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
MX2011006422A (es) | 2008-12-19 | 2011-09-15 | Panima Pharmaceuticals Ag | Autoanticuerpos humanos anti-alfa-sinucleina. |
EA030777B9 (ru) | 2011-06-23 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Анти-альфа-синуклеинсвязывающие молекулы |
US9982008B2 (en) | 2012-06-19 | 2018-05-29 | Intercept Pharmaceuticals, Inc. | Preparation and uses of obeticholic acid |
SG10201607230SA (en) | 2012-06-19 | 2016-10-28 | Intercept Pharmaceuticals Inc | Preparation, Uses And Solid Forms Of Obeticholic Acid |
CA2891348C (en) | 2012-11-28 | 2020-04-28 | Intercept Pharmaceuticals, Inc. | Treatment of pulmonary disease |
SI3594348T1 (sl) | 2013-11-22 | 2022-04-29 | Mina Therapeutics Limited | Sestavki kratko aktivirajoče rna c/ebp alfa in postopki uporabe |
DK3626725T3 (da) * | 2014-05-29 | 2023-02-27 | Bar Pharmaceuticals S R L | Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme |
WO2016045480A1 (zh) * | 2014-09-28 | 2016-03-31 | 上海源力生物技术有限公司 | 一种奥贝胆酸的制备方法 |
CN105585603B (zh) * | 2014-10-21 | 2019-05-24 | 重庆医药工业研究院有限责任公司 | 一种制备奥贝胆酸中间体的方法 |
WO2016073767A1 (en) | 2014-11-06 | 2016-05-12 | Enanta Pharmaceuticals, Inc. | Bile acid analogs an fxr/tgr5 agonists and methods of use thereof |
CN111944006B (zh) * | 2014-11-17 | 2021-12-17 | 正大天晴药业集团股份有限公司 | 新的7-酮-6β-烷基胆烷酸衍生物在制备奥贝胆酸以及其在医药领域的用途 |
TWI688571B (zh) * | 2014-11-19 | 2020-03-21 | 英商Nzp英國有限公司 | 化合物(四) |
WO2016079518A1 (en) * | 2014-11-19 | 2016-05-26 | Dextra Laboratories Limited | 5.beta.-6-alkyl-7-hydroxy-3-one steroids as intermediates for the production of steroidal fxr modulators |
CA2968305A1 (en) * | 2014-11-19 | 2016-05-26 | NZP UK Limited | 6.alpha.-alkyl-3,7-dione steroids as intermediates for the production of steroidal fxr modulators |
DK3221331T3 (da) * | 2014-11-19 | 2019-12-02 | Nzp Uk Ltd | 6-alkyl-7-hydroxy-4-en-3-on-steroider som mellemprodukter til fremstilling af steroide fxr-modulatorer |
US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
CN107231795A (zh) | 2014-11-26 | 2017-10-03 | 英安塔制药有限公司 | 作为fxr/tgr5激动剂的胆汁酸类似物及其使用方法 |
WO2016086115A1 (en) | 2014-11-26 | 2016-06-02 | Enanta Pharmaceuticals, Inc. | Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof |
CN105777835B (zh) * | 2014-12-25 | 2020-02-14 | 重庆药友制药有限责任公司 | 一种制备鹅去氧胆酸类似物的方法 |
CN104558086B (zh) * | 2014-12-25 | 2016-10-05 | 康美(北京)药物研究院有限公司 | 一种5β-3α,7α-二羟基-6α-乙基-胆烷酸的制备方法 |
CN105859814A (zh) * | 2015-01-23 | 2016-08-17 | 江苏奥赛康药业股份有限公司 | 一种奥贝胆酸化合物及其药物组合物 |
EA036404B1 (ru) | 2015-02-06 | 2020-11-06 | Интерсепт Фармасьютикалз, Инк. | Фармацевтические композиции для комбинированной терапии |
US10246483B2 (en) | 2015-02-11 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Bile acid analogs as FXR/TGR5 agonists and methods of use thereof |
CN105985395A (zh) * | 2015-02-13 | 2016-10-05 | 江苏奥赛康药业股份有限公司 | 一种奥贝胆酸化合物及含有该化合物的药物组合物 |
NZ735126A (en) | 2015-03-31 | 2022-10-28 | Enanta Pharm Inc | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
BR112017021311A2 (pt) | 2015-04-07 | 2018-06-26 | Intercept Pharmaceuticals Inc | composições farmacêuticas para terapia de combinação |
CN105777836A (zh) * | 2015-04-09 | 2016-07-20 | 厦门蔚扬药业有限公司 | 奥贝胆酸的多晶型物及其制备方法 |
CN106256833B (zh) * | 2015-06-19 | 2019-01-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 制备3,7-二(三甲基硅基氧基)-6-烯-5β-胆烷-24-酸甲酯的方法 |
CN105294801A (zh) * | 2015-07-02 | 2016-02-03 | 扬子江药业集团南京海陵药业有限公司 | 6-乙基鹅去氧胆酸异构体的合成及其分离测定方法 |
CZ2015504A3 (cs) | 2015-07-16 | 2017-01-25 | Zentiva, K.S. | Krystalické formy obeticholové kyseliny |
CN106397522A (zh) * | 2015-07-31 | 2017-02-15 | 中国人民解放军军事医学科学院毒物药物研究所 | 3,7‑二(叔丁基二甲基硅基氧基)‑6‑烯‑5β‑胆烷‑24‑酸甲酯 |
CN105175473B (zh) * | 2015-08-19 | 2018-12-21 | 丽珠医药集团股份有限公司 | 一种奥贝胆酸晶型i及其制备方法、药物组合物和用途 |
CN105085597B (zh) * | 2015-08-28 | 2017-03-29 | 成都百裕制药股份有限公司 | 一种无定型奥贝胆酸的制备方法 |
CN106478756A (zh) * | 2015-09-02 | 2017-03-08 | 中美华世通生物医药科技(武汉)有限公司 | Oca-e单晶及其制备方法和用途 |
AU2016326428A1 (en) | 2015-09-21 | 2018-04-12 | Intercept Pharmaceuticals, Inc. | Methods of promoting hepatic regeneration |
WO2017053826A1 (en) | 2015-09-24 | 2017-03-30 | Intercept Pharmaceuticals, Inc. | Methods and intermediates for the preparation bile acid derivatives |
CN106589038A (zh) * | 2015-10-15 | 2017-04-26 | 重庆医药工业研究院有限责任公司 | 一种制备3α,7α-二羟基-6α-乙基-5β-胆烷酸的方法 |
CN106632564B (zh) * | 2015-10-30 | 2021-04-13 | 苏州泽璟生物制药股份有限公司 | 奥贝胆酸盐及其无定形物和药物组合物 |
US10604545B2 (en) | 2015-11-06 | 2020-03-31 | Intercept Pharmaceuticals, Inc. | Methods for the preparation of obeticholic acid and derivatives thereof |
CN106749466B (zh) * | 2015-11-23 | 2019-05-21 | 南京济群医药科技股份有限公司 | 一种高纯度奥贝胆酸的制备方法 |
CN105315320B (zh) * | 2015-11-30 | 2017-03-08 | 山东省药学科学院 | 一种制备奥贝胆酸的方法 |
CN106810586A (zh) * | 2015-12-01 | 2017-06-09 | 中美华世通生物医药科技(武汉)有限公司 | 奥贝胆酸晶型ⅱ及其制备方法和用途 |
CN105481925B (zh) * | 2015-12-17 | 2018-06-22 | 南京济群医药科技股份有限公司 | 一种奥贝胆酸及其中间体的制备方法 |
BR112018012590A2 (pt) * | 2015-12-22 | 2018-12-04 | Intercept Pharmaceuticals Inc | formas cristalinas polimórficas do ácido obeticólico |
CN105646633B (zh) * | 2016-01-22 | 2020-05-26 | 南京长澳医药科技有限公司 | 一种制备奥贝胆酸1型的方法 |
CN108779141A (zh) | 2016-02-10 | 2018-11-09 | 雷迪博士实验室有限公司 | 奥贝胆酸的胺盐 |
WO2017147137A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof |
US10364267B2 (en) | 2016-02-23 | 2019-07-30 | Enanta Pharmaceuticals, Inc. | Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
WO2017147174A1 (en) | 2016-02-23 | 2017-08-31 | Enanta Pharmaceuticals, Inc. | Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof |
CN105541953B (zh) * | 2016-03-15 | 2017-11-21 | 成都市新功生物科技有限公司 | 一种高纯度奥贝胆酸的重结晶纯化方法 |
CN105585605A (zh) * | 2016-03-15 | 2016-05-18 | 成都市新功生物科技有限公司 | 一种奥贝胆酸中间体的合成方法 |
WO2017174515A1 (en) | 2016-04-04 | 2017-10-12 | Dipharma Francis S.R.L. | Method for preparing a farnesoid x receptor agonist |
CA3020698A1 (en) | 2016-04-13 | 2017-10-19 | Intercept Pharmaceuticals, Inc. | Methods of treating or preventing hepatocellular carcinoma |
TW201738254A (zh) | 2016-04-19 | 2017-11-01 | 英特賽普醫藥品公司 | 奧貝膽酸及其衍生物之製備方法 |
GB201608776D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
GB201608777D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Compounds |
GB201608779D0 (en) * | 2016-05-18 | 2016-06-29 | Dextra Lab Ltd | Methods and compounds |
CN107400154A (zh) * | 2016-05-18 | 2017-11-28 | 北京凯因科技股份有限公司 | 一种制备3α,7α-二-羟基-6α-乙基-5β-胆烷酸的方法 |
CN106046094A (zh) * | 2016-05-30 | 2016-10-26 | 福建广生堂药业股份有限公司 | 一种奥贝胆酸二聚体杂质及其制备方法 |
WO2017207648A1 (en) | 2016-05-31 | 2017-12-07 | Bionice, S.L.U | Process and intermediates for the preparation of obeticholic acid and derivatives thereof |
WO2017208165A1 (en) | 2016-06-01 | 2017-12-07 | Dr. Reddy’S Laboratories Limited | Process for preparation of obeticholic acid |
CN106083971B (zh) * | 2016-06-17 | 2017-11-14 | 苏州敬业医药化工有限公司 | 一种(E)‑3α‑羟基‑6‑亚乙基‑7‑酮‑5β‑胆烷‑24‑酸的制备方法 |
CZ2016385A3 (cs) | 2016-06-28 | 2018-01-10 | Zentiva, K.S. | Způsoby přípravy intermediátů pro syntézu Obeticholové kyseliny |
TW201802103A (zh) * | 2016-07-13 | 2018-01-16 | 江蘇恆瑞醫藥股份有限公司 | 一種奧貝膽酸及其中間體的製備方法 |
CN107663221A (zh) * | 2016-07-27 | 2018-02-06 | 南京长澳医药科技有限公司 | 一种奥贝胆酸的制备方法 |
CN106279335A (zh) * | 2016-08-12 | 2017-01-04 | 齐鲁制药有限公司 | 一种制备奥贝胆酸及其中间体的方法 |
EP3287467A1 (de) | 2016-08-22 | 2018-02-28 | ratiopharm GmbH | Herstellung von obeticholsäure mit kontinuierlichen durchflussprozessschritten |
CN109641934B (zh) * | 2016-09-20 | 2021-07-02 | 江苏豪森药业集团有限公司 | 胆酸衍生物游离碱,晶型及其制备方法和应用 |
CN106478757B (zh) * | 2016-09-27 | 2019-01-18 | 华南理工大学 | 一种3α,7α-二羟基-6α-乙基胆烷酸的制备方法 |
CN107936078A (zh) * | 2016-10-13 | 2018-04-20 | 上海科胜药物研发有限公司 | 一种制备奥贝胆酸的新方法 |
CN108070014A (zh) * | 2016-11-08 | 2018-05-25 | 北京藏卫信康医药研发有限公司 | 一种化合物的制备方法及其在制备奥贝胆酸中的应用 |
AU2017368069B2 (en) * | 2016-11-29 | 2021-07-08 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonylurea bile acid derivatives |
CN108117579A (zh) * | 2016-11-29 | 2018-06-05 | 昆明积大制药股份有限公司 | 奥贝胆酸及其中间体的制备方法 |
US10472386B2 (en) | 2017-02-14 | 2019-11-12 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR agonists and methods of use thereof |
CN108456238A (zh) * | 2017-02-20 | 2018-08-28 | 浙江京新药业股份有限公司 | 奥贝胆酸衍生物及奥贝胆酸的制备方法 |
WO2018153933A1 (en) | 2017-02-21 | 2018-08-30 | Genfit | Combination of a ppar agonist with a fxr agonist |
CA3058754A1 (en) | 2017-04-07 | 2018-10-11 | Enanta Pharmaceuticals, Inc. | Process for preparation of sulfonyl carbamate bile acid derivatives |
WO2018194426A1 (ko) * | 2017-04-20 | 2018-10-25 | 대웅바이오 주식회사 | 연속흐름반응을 이용한 담즙산 유도체의 제조 방법 |
CN107298694A (zh) * | 2017-04-21 | 2017-10-27 | 华东师范大学 | 奥贝胆酸的合成方法及其中间体 |
CZ2017298A3 (cs) | 2017-05-26 | 2018-12-05 | Zentiva, K.S. | Amorfní formy obeticholové kyseliny |
EP3431486A1 (de) | 2017-07-18 | 2019-01-23 | Bionice, S.L.U. | Verfahren und zwischenprodukte zur synthese von obeticholsäure und derivaten davon |
CN111328332B (zh) | 2017-08-03 | 2023-01-24 | 玫帝托克斯股份有限公司 | 用于制备胆汁酸类的方法 |
TW201920669A (zh) | 2017-09-08 | 2019-06-01 | 英商美納治療公司 | HNF4a saRNA組成物和使用方法 |
CN108299539B (zh) * | 2018-03-09 | 2021-07-06 | 中山百灵生物技术股份有限公司 | 利用连续流微反应器生产6-亚乙基鹅去氧胆酸的方法 |
CN110655550A (zh) * | 2018-06-29 | 2020-01-07 | 江苏海悦康医药科技有限公司 | (E)-3α-羟基-6-亚乙基-7-氧代-5β-胆甾烷-24-酸的制备方法 |
GB201812382D0 (en) | 2018-07-30 | 2018-09-12 | Nzp Uk Ltd | Compounds |
WO2020039449A1 (en) | 2018-08-24 | 2020-02-27 | Solara Active Pharma Sciences Limited | An improved process for the preparation of obeticholic acid and intermediates used in the process thereof |
CN109485686B (zh) * | 2018-12-27 | 2021-08-27 | 重庆华邦胜凯制药有限公司 | 一种提高琥珀酸甲泼尼龙杂质合成中关键中间体6β含量的方法 |
CN111718388A (zh) | 2019-03-19 | 2020-09-29 | 苏州泽璟生物制药股份有限公司 | 鹅去氧胆酸衍生物的制备方法 |
US20220226350A1 (en) | 2019-05-30 | 2022-07-21 | Intercept Pharmaceuticals, Inc. | Pharmaceutical compositions comprising a fxr agonist and a fibrate for use in the treatment of cholestatic liver disease |
CN112898369A (zh) * | 2019-12-04 | 2021-06-04 | 博瑞生物医药(苏州)股份有限公司 | 用于制备奥贝胆酸的方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3366932D1 (en) | 1982-07-29 | 1986-11-20 | Lehner Ag | New derivatives of biliary acids, process for the production thereof and pharmaceutical compositions containing the same |
IT1206112B (it) | 1983-04-29 | 1989-04-14 | Lehner Ag | Nuovi derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
IT1212835B (it) | 1983-08-18 | 1989-11-30 | Lehner Ag | Derivati di acidi biliari, procedimento per la loro preparazione e relative composizioni farmaceutiche. |
US4892868A (en) | 1984-08-17 | 1990-01-09 | Gipharmex, S.P.A. | Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions |
IT1196377B (it) | 1984-12-21 | 1988-11-16 | Lehner Ag | Derivati di acidi biliari,procedimento per la loro preparazione e relative composizioni farmaceutiche |
IT1223313B (it) * | 1987-10-20 | 1990-09-19 | Gipharmex Spa | Derivati di acidi biliari loro preparazione e composizioni farmaceutiche che li contengono |
US5175320A (en) | 1989-04-17 | 1992-12-29 | Giuliani S.P.A. | Fluorinated bile acid derivatives, processes for the preparation thereof and pharmaceutical compositions containing them |
IT1229570B (it) | 1989-04-17 | 1991-09-04 | Giuliani Spa | Derivati fluorurati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono. |
DE69018592T2 (de) | 1989-12-13 | 1995-10-05 | Mitsubishi Chem Corp | Pyrazolylacrylsäure-Derivate, verwendbar als systemische Fungiziden in Pflanzen- und Materialschutz. |
WO1997028149A1 (en) | 1996-02-02 | 1997-08-07 | Merck & Co., Inc. | Method for raising hdl cholesterol levels |
GB9604242D0 (en) | 1996-02-28 | 1996-05-01 | Glaxo Wellcome Inc | Chemical compounds |
GB9606805D0 (en) | 1996-03-30 | 1996-06-05 | Glaxo Wellcome Inc | Medicaments |
AU3552697A (en) | 1996-07-12 | 1998-02-09 | Smithkline Beecham Plc | Novel treatment of leptine resistance |
US6008237A (en) | 1997-12-19 | 1999-12-28 | Merck & Co., Inc. | Arylthiazolidinedione derivatives |
ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
JP2002528721A (ja) | 1998-10-23 | 2002-09-03 | グラクソ グループ リミテッド | 核内受容体のリガンド用のアッセイ |
ES2326850T3 (es) | 1998-12-23 | 2009-10-20 | Glaxo Group Limited | Ensayos para ligandos de receptores nucleares. |
US6465258B1 (en) | 1999-01-07 | 2002-10-15 | Tularik, Inc. | FXR receptor-mediated modulation cholesterol metabolism |
AU780658B2 (en) | 1999-03-26 | 2005-04-07 | City Of Hope | Method of affecting cholesterol catabolism using nuclear bile acid receptor |
US20020132223A1 (en) | 1999-03-26 | 2002-09-19 | City Of Hope | Methods for modulating activity of the FXR nuclear receptor |
EP1473042B1 (de) | 1999-03-26 | 2006-06-21 | City of Hope | Selektion von FXR-Rezeptormodulatoren |
US6906057B1 (en) | 1999-06-11 | 2005-06-14 | Allergan, Inc. | Methods for modulating FXR receptor activity |
DE60023493T2 (de) | 1999-06-11 | 2006-07-20 | Allergan, Inc., Irvine | Verwendung von synthetischen FXR Liganden zur Behandlung von Krankheiten die mit einem gestörten Gleichgewicht des Cholesterin-Spiegels verbunden sind und von Kolonkrebs |
US6559188B1 (en) | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
WO2001030343A1 (en) | 1999-10-22 | 2001-05-03 | Merck & Co., Inc. | Pharmaceuticals for treating obesity |
US6627636B2 (en) | 2000-06-15 | 2003-09-30 | Bristol-Myers Squibb Company | HMG-CoA reductase inhibitors and method |
WO2002020463A2 (en) | 2000-09-05 | 2002-03-14 | Tularik Inc. | Fxr modulators |
US20020119958A1 (en) | 2001-02-13 | 2002-08-29 | Shinichiro Tojo | Therapeutic agent for hyperlipidemia |
ATE303399T1 (de) * | 2001-03-12 | 2005-09-15 | Intercept Pharmaceuticals Inc | Steroide als agonisten für fxr |
EP1378749A4 (de) | 2001-04-12 | 2005-05-11 | Takeda Pharmaceutical | Screening-verfahren |
WO2003016280A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
WO2003015777A1 (en) | 2001-08-13 | 2003-02-27 | Lion Bioscience Ag | Nr1h4 nuclear receptor binding compounds |
US20030144360A1 (en) | 2001-11-19 | 2003-07-31 | Allergan Sales, Inc. | Composition and method for modulating BAR/FXR receptor activity |
AU2003225903A1 (en) * | 2002-03-21 | 2003-10-08 | Curagen Corporation | Methods of using farnesoid x receptor (fxr) agonists |
EP1494533A2 (de) | 2002-04-12 | 2005-01-12 | The University of Chicago | Farnesoid-x-aktivierte rezeptoragonisten |
US6987121B2 (en) | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
CA2492058A1 (en) | 2002-06-19 | 2003-12-31 | Availvs Corporation | Artificial stone wall material |
WO2004048349A1 (en) | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
EP1696910A4 (de) | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | Zusammensetzungen und verfahren zur behandlung von fibrose |
EP1568706A1 (de) * | 2004-02-26 | 2005-08-31 | Intercept Pharmaceuticals, Inc. | Neuer Steroid-Agonist für FXR |
PL1734970T3 (pl) | 2004-03-12 | 2015-05-29 | Intercept Pharmaceuticals Inc | Leczenie zwłóknienia z zastosowaniem ligandów FXR |
ITMI20050912A1 (it) | 2005-05-19 | 2006-11-20 | Erregierre Spa | Processo di preparazione di acidi 3-a-ya(b)-diidrossi-6-a(b)-alchil-5b-colanici |
AU2007265457C1 (en) | 2006-06-27 | 2012-11-29 | Intercept Pharmaceuticals, Inc. | Bile acid derivatives as FXR ligands for the prevention or treatment of FXR-mediated diseases or conditions |
EP1947108A1 (de) | 2007-01-19 | 2008-07-23 | Intercept Pharmaceuticals, Inc. | TGR5-Modulatoren und Anwendungsverfahren dafür |
ES2438271T3 (es) | 2007-01-19 | 2014-01-16 | Intercept Pharmaceuticals, Inc. | Ácidos biliares 23-sustituidos como moduladores de TGR5 y métodos de uso de los mismos |
DK2698375T3 (en) | 2008-11-19 | 2018-05-28 | Intercept Pharmaceuticals Inc | TGR5 modulators and methods for using them |
-
2005
- 2005-05-19 IT IT000912A patent/ITMI20050912A1/it unknown
-
2006
- 2006-05-19 WO PCT/EP2006/062446 patent/WO2006122977A2/en not_active Application Discontinuation
- 2006-05-19 CN CN2006800170256A patent/CN101203526B/zh not_active Expired - Fee Related
- 2006-05-19 JP JP2008511719A patent/JP5127700B2/ja not_active Expired - Fee Related
- 2006-05-19 DE DE602006011457T patent/DE602006011457D1/de active Active
- 2006-05-19 US US11/914,559 patent/US7994352B2/en active Active
- 2006-05-19 ES ES06763188T patent/ES2338698T3/es active Active
- 2006-05-19 AT AT06763188T patent/ATE453657T1/de active
- 2006-05-19 AU AU2006248906A patent/AU2006248906B2/en not_active Ceased
- 2006-05-19 CA CA2608539A patent/CA2608539C/en active Active
- 2006-05-19 DK DK06763188.7T patent/DK1888614T3/da active
- 2006-05-19 EP EP06763188A patent/EP1888614B1/de active Active
Also Published As
Publication number | Publication date |
---|---|
JP2008540612A (ja) | 2008-11-20 |
ES2338698T3 (es) | 2010-05-11 |
WO2006122977A2 (en) | 2006-11-23 |
CA2608539C (en) | 2013-02-26 |
AU2006248906A1 (en) | 2006-11-23 |
CN101203526A (zh) | 2008-06-18 |
CA2608539A1 (en) | 2006-11-23 |
ITMI20050912A1 (it) | 2006-11-20 |
DE602006011457D1 (de) | 2010-02-11 |
US7994352B2 (en) | 2011-08-09 |
CN101203526B (zh) | 2012-09-05 |
AU2006248906B2 (en) | 2012-04-12 |
WO2006122977A3 (en) | 2007-01-18 |
JP5127700B2 (ja) | 2013-01-23 |
EP1888614A2 (de) | 2008-02-20 |
DK1888614T3 (da) | 2010-05-10 |
EP1888614B1 (de) | 2009-12-30 |
US20080214515A1 (en) | 2008-09-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE453657T1 (de) | Verfahren zur herstellung von 3alpha(beta)- | |
ATE445019T1 (de) | Verfahren zur enzymatischen herstellung von (s)-3-cyano-5-methylhexansäure | |
ATE430480T1 (de) | Verfahren zur herstellung von nährmittelzusammensetzungen | |
ATE486857T1 (de) | Verfahren zur herstellung von telmisartan | |
ATE408604T1 (de) | Verfahren zur herstellung von 1-alkyl-3- phenyluracilen | |
ATE435209T1 (de) | Verfahren zur herstellung von montelukast-natrium | |
DE502005010038D1 (de) | Verfahren zur herstellung von 3-pentennitril | |
ATE427997T1 (de) | Verfahren zur herstellung von alkylestern | |
ATE542803T1 (de) | Verfahren zur herstellung von dihydrochinazolinen | |
DE502005003669D1 (de) | Verfahren zur herstellung von emulsionen von hochviskosen organopolysiloxanen | |
ATE444303T1 (de) | Verfahren zur herstellung von ferrisuccinylcasein | |
ATE489352T1 (de) | Verfahren zur herstellung von brenztraubensäure | |
DE102004035617B8 (de) | Verfahren zur Herstellung von Substraten für Fotomaskenrohlinge | |
DE602004027229D1 (de) | Verfahren zur herstellung von photonischer kristallfaser | |
ATE405374T1 (de) | Verfahren zur herstellung von brillengläsern | |
DE602005004221D1 (de) | Verfahren zur Herstellung von Faserformkörpern | |
ATE459575T1 (de) | Verfahren zur herstellung von blausäure | |
ATE441636T1 (de) | Verfahren zur herstellung von carboxaniliden | |
ATE438613T1 (de) | Verfahren zur herstellung von anilinen | |
DE502005006272D1 (de) | Verfahren zur herstellung von semicarbazonen | |
DE602006011824D1 (de) | Verfahren zur Herstellung von Schlämmen | |
ATE553080T1 (de) | Verkürztes verfahren zur herstellung von l- lobelin | |
ATE405554T1 (de) | Verfahren zur herstellung von pramipexole | |
ATE341558T1 (de) | Verfahren zur herstellung von topiramate | |
ATE529382T1 (de) | Verbessertes verfahren zur herstellung von blausäure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1888614 Country of ref document: EP |